Aduro Biotech Company Profile (NASDAQ:ADRO)

About Aduro Biotech

Aduro Biotech logoAduro Biotech, Inc. is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies. Its LADD product candidates include CRS-207, ADU-623, ADU-741 and ADU-214. Its STING Activator product candidates include ADU-S100. Its LADD technology platform is engineered to express tumor-associated antigens to induce specific and targeted immune responses. Its STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a tumor-specific immune response. Its B-select monoclonal antibody platform includes various immune modulating assets in research and preclinical development.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ADRO
  • CUSIP:
Key Metrics:
  • Previous Close: $11.15
  • 50 Day Moving Average: $11.49
  • 200 Day Moving Average: $12.59
  • 52-Week Range: $7.26 - $17.72
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.57
  • P/E Growth: 0.07
  • Market Cap: $762.52M
  • Outstanding Shares: 67,182,000
  • Beta: 3.83
Profitability:
  • Net Margins: -72.04%
  • Return on Equity: -23.45%
  • Return on Assets: -12.40%
Debt:
  • Current Ratio: 11.11%
  • Quick Ratio: 11.11%
Additional Links:
Companies Related to Aduro Biotech:

Analyst Ratings

Consensus Ratings for Aduro Biotech (NASDAQ:ADRO) (?)
Ratings Breakdown: 1 Sell Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $19.60 (72.69% upside)

Analysts' Ratings History for Aduro Biotech (NASDAQ:ADRO)
Show:
DateFirmActionRatingPrice TargetDetails
1/19/2017Canaccord GenuitySet Price TargetBuy$30.00View Rating Details
11/25/2016Roth CapitalReiterated RatingBuy$20.00View Rating Details
11/22/2016FBR & CoReiterated RatingBuyView Rating Details
10/24/2016Leerink SwannSet Price TargetBuy$14.00View Rating Details
3/15/2016Bank of America CorpDowngradeBuy -> Underperform$32.00 -> $14.00View Rating Details
2/2/2016William BlairInitiated CoverageBuyView Rating Details
12/1/2015Oppenheimer Holdings, Inc.DowngradeOutperform -> Market PerformView Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Aduro Biotech (NASDAQ:ADRO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2017        
11/2/2016($0.45)($0.54)$3.99 million$3.79 millionViewN/AView Earnings Details
8/3/2016($0.18)$0.03$25.24 million$39.00 millionViewN/AView Earnings Details
5/2/2016Q116($0.25)($0.45)ViewN/AView Earnings Details
3/8/2016Q415($0.15)$0.04$34.38 millionViewN/AView Earnings Details
11/24/2015Q3($0.08)$0.01$15.80 million$19.15 millionViewN/AView Earnings Details
8/10/2015Q215($0.01)($0.50)$1.00 million$9.90 millionViewN/AView Earnings Details
5/28/2015Q115($0.03)($39.97)$9.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aduro Biotech (NASDAQ:ADRO)
Current Year EPS Consensus Estimate: $-1.35 EPS
Next Year EPS Consensus Estimate: $-1.50 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20168($0.52)($0.10)($0.29)
Q2 20167($0.46)$0.11($0.18)
Q3 20167($0.52)($0.20)($0.43)
Q4 20167($0.56)($0.21)($0.40)
Q1 20171($0.50)($0.50)($0.50)
Q2 20171($0.50)($0.50)($0.50)
Q3 20171($0.51)($0.51)($0.51)
Q4 20171($0.51)($0.51)($0.51)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aduro Biotech (NASDAQ:ADRO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aduro Biotech (NASDAQ:ADRO)
Insider Ownership Percentage: 6.50%
Institutional Ownership Percentage: 35.52%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/17/2017Dirk G BrockstedtEVPSell8,000$11.86$94,880.00View SEC Filing  
1/11/2017Blaine TemplemanVPSell3,785$11.95$45,230.75View SEC Filing  
1/3/2017Stephen T IsaacsInsiderSell27,273$11.12$303,275.76View SEC Filing  
12/1/2016Thomas W DubenskyInsiderSell25,000$10.94$273,500.00View SEC Filing  
11/14/2016Ross HaghighatDirectorSell7,088$15.50$109,864.00View SEC Filing  
10/3/2016Stephen T IsaacsCEOSell27,273$12.67$345,548.91View SEC Filing  
10/3/2016Thomas W DubenskyInsiderSell25,000$12.68$317,000.00View SEC Filing  
9/19/2016Jennifer LewInsiderSell6,360$14.95$95,082.00View SEC Filing  
9/1/2016Thomas W DubenskyInsiderSell25,000$14.03$350,750.00View SEC Filing  
8/11/2016Thomas W DubenskyInsiderSell25,000$15.18$379,500.00View SEC Filing  
7/5/2016Thomas W DubenskyInsiderSell25,000$11.61$290,250.00View SEC Filing  
5/16/2016Thomas W. DubenskyInsiderSell905$8.20$7,421.00View SEC Filing  
1/11/2016Dirk G. BrockstedtVPSell22,000$21.77$478,940.00View SEC Filing  
1/8/2016Gregory W. SchaferCOOSell20,000$23.58$471,600.00View SEC Filing  
1/6/2016Jennifer LewVPSell5,242$25.71$134,771.82View SEC Filing  
1/5/2016Stephen T. IsaacsCEOSell25,000$26.31$657,750.00View SEC Filing  
1/4/2016Thomas W. DubenskyinsiderSell15,000$26.37$395,550.00View SEC Filing  
12/7/2015Gregory W. SchaferCOOSell25,000$29.74$743,500.00View SEC Filing  
12/3/2015Jennifer LewVPSell5,242$29.85$156,473.70View SEC Filing  
12/1/2015Stephen T. IsaacsCEOSell25,000$29.11$727,750.00View SEC Filing  
12/1/2015Thomas W. DubenskyinsiderSell30,000$29.27$878,100.00View SEC Filing  
11/18/2015Jennifer LewVPSell6,712$28.52$191,426.24View SEC Filing  
11/17/2015Gregory W. SchaferCOOSell26,470$28.15$745,130.50View SEC Filing  
11/17/2015Thomas W. DubenskyinsiderSell31,470$28.27$889,656.90View SEC Filing  
11/16/2015Stephen T. IsaacsCEOSell25,000$27.54$688,500.00View SEC Filing  
4/20/2015Jennifer LewVPBuy2,000$17.00$34,000.00View SEC Filing  
4/20/2015Venture (Vi) Inves MorningsideMajor ShareholderBuy441,176$17.00$7,499,992.00View SEC Filing  
4/20/2015William Mariner GreenmanDirectorBuy3,000$17.00$51,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aduro Biotech (NASDAQ:ADRO)
DateHeadline
News IconAnalysts Peer Into Their Crystal Balls For Aduro BioTech Inc (NASDAQ:ADRO): Where Is It headed? - Winfield Review (NASDAQ:ADRO)
winfieldreview.com - February 23 at 8:45 PM
News IconStock Update: Estimates & Target in Focus for Aduro BioTech Inc (NASDAQ:ADRO) - Aiken Advocate (NASDAQ:ADRO)
aikenadvocate.com - February 23 at 1:23 AM
News IconTrading Scope: Checking on Shares of Aduro BioTech, Inc. (NASDAQ:ADRO) - Baldwin Journal (NASDAQ:ADRO)
baldwinjournal.com - February 22 at 8:21 PM
News IconInvestors are Watching Shares of Aduro BioTech, Inc. (NASDAQ:ADRO) - BVN (NASDAQ:ADRO)
bvnewsjournal.com - February 21 at 3:37 PM
News IconWall Street Ratings Review on ChemoCentryx, Inc. (NASDAQ:CCXI) Aduro BioTech, Inc. (NASDAQ:ADRO) - Sherwood Daily (NASDAQ:ADRO)
sherwooddaily.com - February 21 at 5:58 AM
News IconInvestor Center: Looking at the Numbers for Aduro BioTech, Inc. (NASDAQ:ADRO) - Rives Journal (NASDAQ:ADRO)
rivesjournal.com - February 18 at 9:27 AM
News IconShares in Focus: Aduro BioTech, Inc. (NASDAQ:ADRO) - Piedmont Register (NASDAQ:ADRO)
piedmontregister.com - February 14 at 8:37 PM
News IconStreet Session Update on Aduro BioTech Inc (NASDAQ:ADRO) - Rockville Register (NASDAQ:ADRO)
rockvilleregister.com - February 13 at 8:33 PM
globenewswire.com logoAduro Biotech to Present at the Leerink Partners 6th Annual Global Healthcare Conference - GlobeNewswire (press release) (NASDAQ:ADRO)
globenewswire.com - February 11 at 3:19 PM
finance.yahoo.com logoAduro Biotech to Present at the Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:ADRO)
finance.yahoo.com - February 10 at 3:42 PM
capitalcube.com logoAduro BioTech, Inc. breached its 50 day moving average in a Bullish Manner : ADRO-US : February 1, 2017 (NASDAQ:ADRO)
www.capitalcube.com - February 1 at 3:27 PM
News IconAduro BioTech Inc ADRO Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:ADRO)
www.bioportfolio.com - January 28 at 9:04 PM
News IconLooking Ahead for Aduro BioTech Inc (NASDAQ:ADRO); Are These Shares Ready to Go Higher? - Aiken Advocate (NASDAQ:ADRO)
aikenadvocate.com - January 26 at 3:35 PM
finance.yahoo.com logoAduro Biotech Announces Appointment of Leading Immunotherapy and Oncology Experts to Scientific Advisory Board (NASDAQ:ADRO)
finance.yahoo.com - January 26 at 3:35 PM
News IconStock Spotlight: Zooming in on Shares of Aduro BioTech, Inc. (NASDAQ:ADRO) - The Tribune (NASDAQ:ADRO)
lakecitytribune.com - January 26 at 1:30 AM
News IconCan This Stock Gain Traction: Aduro BioTech, Inc. (NASDAQ:ADRO) - Prospect Journal (NASDAQ:ADRO)
prospectjournal.com - January 23 at 8:23 PM
investornewswire.com logoAduro BioTech Inc (NASDAQ:ADRO) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:ADRO)
www.investornewswire.com - January 22 at 3:19 PM
4-traders.com logoInsider Trading Activity Aduro Biotech Inc. (NASDAQ:ADRO) – EVP Sold 8,000 shares of Stock (NASDAQ:ADRO)
www.4-traders.com - January 21 at 1:27 AM
us.rd.yahoo.com logoAduro Biotech Enters into Exclusive License Agreement for Proprietary Neoantigen Identification Technology (NASDAQ:ADRO)
us.rd.yahoo.com - January 21 at 1:27 AM
us.rd.yahoo.com logo8:02 am Aduro Biotech enters into exclusive license agreement with Stanford University for Neoantigen identification technology; terms not disclosed (NASDAQ:ADRO)
us.rd.yahoo.com - January 21 at 1:27 AM
News IconTrading Corner: Eye on Technical Levels for Aduro Biotech Inc. (ADRO) - Sherwood Daily (NASDAQ:ADRO)
sherwooddaily.com - January 20 at 3:24 PM
marketexclusive.com logoInsider Trading Activity Aduro Biotech Inc. (NASDAQ:ADRO) – EVP Sold 8000 shares of Stock - Market Exclusive (NASDAQ:ADRO)
marketexclusive.com - January 20 at 3:24 PM
finance.yahoo.com logoAduro (ADRO) Inks License Agreement with Stanford University (NASDAQ:ADRO)
finance.yahoo.com - January 20 at 3:24 PM
finance.yahoo.com logoAduro Biotech Enters into Exclusive License Agreement for Proprietary Neoantigen Identification Technology - Yahoo Finance (NASDAQ:ADRO)
finance.yahoo.com - January 19 at 8:35 PM
News IconAnalyst Consensus Estimates & Projections are in For Shares of Aduro BioTech Inc (NASDAQ:ADRO) - Aiken Advocate (NASDAQ:ADRO)
aikenadvocate.com - January 19 at 3:34 PM
News IconTrading Watch: ADX and CCI Review for Aduro Biotech Inc. (ADRO) - Sherwood Daily (NASDAQ:ADRO)
sherwooddaily.com - January 18 at 8:50 PM
News IconShooting From the Hip, Stock Reaches Most Volatile List: Aduro BioTech, Inc. (NASDAQ:ADRO) - Wall Street Beacon (NASDAQ:ADRO)
wsbeacon.com - January 18 at 8:50 PM
capitalcube.com logoETFs with exposure to Aduro BioTech, Inc. : January 17, 2017 (NASDAQ:ADRO)
www.capitalcube.com - January 17 at 3:51 PM
News IconInside Track: Trading Focus on Shares of Aduro Biotech Inc. (ADRO) - Springdale Times (NASDAQ:ADRO)
springdaletimes.com - January 17 at 10:14 AM
News IconWill The Needle Move For Aduro BioTech Inc (NASDAQ:ADRO) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:ADRO)
wsbeacon.com - January 17 at 10:14 AM
capitalcube.com logoAduro BioTech, Inc. breached its 50 day moving average in a Bullish Manner : ADRO-US : January 16, 2017 (NASDAQ:ADRO)
www.capitalcube.com - January 16 at 11:53 AM
investornewswire.com logoAduro BioTech Inc (NASDAQ:ADRO) Strong Sell Recommendations At {RATING_CNT_STRONG_SELLS:378}} - Investor Newswire (NASDAQ:ADRO)
www.investornewswire.com - January 15 at 3:19 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Aduro BioTech, Inc. (NASDAQ:ADRO) - Wall Street Beacon (NASDAQ:ADRO)
wsbeacon.com - January 15 at 1:22 AM
News IconStock Edging Lower Out Of The Gate: Aduro BioTech, Inc. (NASDAQ:ADRO) - Wall Street Beacon (NASDAQ:ADRO)
wsbeacon.com - January 12 at 3:22 PM
investornewswire.com logoSales Of Aduro BioTech Inc (NASDAQ:ADRO) Expected At $219.76 - Investor Newswire (NASDAQ:ADRO)
www.investornewswire.com - January 12 at 1:33 AM
News IconAnalysts Projecting Upside, Can This Stock Surge Higher: Aduro BioTech, Inc. (NASDAQ:ADRO) - Prospect Journal (NASDAQ:ADRO)
prospectjournal.com - January 10 at 3:19 PM
tmcnet.com logoAduro Biotech Announces Clinical Collaboration with Merck to … (NASDAQ:ADRO)
www.tmcnet.com - January 9 at 8:35 PM
marketexclusive.com logoAduro Biotech, Inc. (NASDAQ:ADRO) Files An 8-K Other Events - Market Exclusive (NASDAQ:ADRO)
marketexclusive.com - January 9 at 3:33 PM
finance.yahoo.com logoAduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduro’s CRS-207 with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Gastric Cancer (NASDAQ:ADRO)
finance.yahoo.com - January 9 at 3:33 PM
finance.yahoo.com logo8:02 am Aduro Biotech announces a a clinical collaboration with Merck (MRK (NASDAQ:ADRO)
finance.yahoo.com - January 9 at 3:33 PM
biz.yahoo.com logoADURO BIOTECH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:ADRO)
biz.yahoo.com - January 9 at 3:33 PM
capitalcube.com logoAduro BioTech, Inc. – Value Analysis (NASDAQ:ADRO) : January 9, 2017 (NASDAQ:ADRO)
www.capitalcube.com - January 9 at 3:33 PM
investornewswire.com logoCan Shares Of Aduro BioTech Inc (NASDAQ:ADRO) Hit $20? - Investor Newswire (NASDAQ:ADRO)
www.investornewswire.com - January 8 at 3:20 PM
News IconHome Business Aduro Biotech Inc. (ADRO) Stock Price Target Moved to $30.00 at Canaccord... - BNB Daily (blog) (NASDAQ:ADRO)
www.baseball-news-blog.com - January 8 at 3:20 PM
capitalcube.com logoAduro BioTech, Inc. breached its 50 day moving average in a Bullish Manner : ADRO-US : January 6, 2017 (NASDAQ:ADRO)
www.capitalcube.com - January 6 at 3:27 PM
publicnow.com logoAnnouncement from PT Adaro Energy Tbk - Ir Soebianto (NASDAQ:ADRO)
www.publicnow.com - January 4 at 3:25 PM
publicnow.com logoCurrency Conversion Rate for 2016 Interim Dividend Payment (NASDAQ:ADRO)
www.publicnow.com - January 3 at 8:06 AM
publicnow.com logoClean Energy ‘Moving Forward’ Despite Trump’s E.P.A. Pick, Experts Say (NASDAQ:ADRO)
www.publicnow.com - December 29 at 3:23 PM
publicnow.com logoEnergy thinktank cuts coal demand forecast for fifth year in row (NASDAQ:ADRO)
www.publicnow.com - December 29 at 3:23 PM
publicnow.com logoCoal in Trump’s Stocking (NASDAQ:ADRO)
www.publicnow.com - December 29 at 3:23 PM

Social

What is Aduro Biotech's stock symbol?

Aduro Biotech trades on the NASDAQ under the ticker symbol "ADRO."

Where is Aduro Biotech's stock going? Where will Aduro Biotech's stock price be in 2017?

5 brokers have issued 12 month price targets for Aduro Biotech's shares. Their forecasts range from $14.00 to $30.00. On average, they expect Aduro Biotech's stock price to reach $19.60 in the next twelve months.

When will Aduro Biotech announce their earnings?

Aduro Biotech is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.

Who owns Aduro Biotech stock?

Aduro Biotech's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (4.24%), State Street Corp (0.85%), Clough Capital Partners L P (0.49%), Baillie Gifford & Co. (0.43%), Artal Group S.A. (0.15%) and Russell Investments Group Ltd. (0.04%). Company insiders that own Aduro Biotech stock include Blaine Templeman, Dirk G Brockstedt, Gregory W Schafer, Jennifer Lew, Ross Haghighat, Stephen T Isaacs, Thomas W Dubensky, Venture (Vi) Inves Morningside and William Mariner Greenman.

Who sold Aduro Biotech stock? Who is selling Aduro Biotech stock?

Aduro Biotech's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and First Republic Investment Management Inc.. Company insiders that have sold Aduro Biotech stock in the last year include Blaine Templeman, Dirk G Brockstedt, Jennifer Lew, Ross Haghighat, Stephen T Isaacs and Thomas W Dubensky.

Who bought Aduro Biotech stock? Who is buying Aduro Biotech stock?

Aduro Biotech's stock was acquired by a variety of institutional investors in the last quarter, including Clough Capital Partners L P, Russell Investments Group Ltd., Renaissance Technologies LLC, Tudor Investment Corp Et Al and State Street Corp. Company insiders that have bought Aduro Biotech stock in the last two years include Jennifer Lew, Venture (Vi) Inves Morningside and William Mariner Greenman.

How do I buy Aduro Biotech stock?

Shares of Aduro Biotech can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Aduro Biotech stock cost?

One share of Aduro Biotech stock can currently be purchased for approximately $11.35.

Aduro Biotech (NASDAQ:ADRO) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Aduro Biotech (NASDAQ:ADRO)

Earnings History Chart

Earnings by Quarter for Aduro Biotech (NASDAQ:ADRO)

Dividend History Chart

Dividend Payments by Quarter for Aduro Biotech (NASDAQ:ADRO)

Last Updated on 2/25/2017 by MarketBeat.com Staff